" /> Bebtelovimab - CISMeF





Preferred Label : Bebtelovimab;

NCIt related terms : Monoclonal antibodies against SARS-CoV-2: bebtelovimab;

NCIt definition : A neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, bebtelovimab specifically targets and binds to the receptor-binding domain (RBD) of SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : 8YL4SYR6CU;

CAS number : 2578319-11-4;

Molecule name : LY 3853113; LY-CoV1404; LY CoV1404; LY-3853113;

NCI Metathesaurus CUI : CL1770614;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
30/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.